EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors

John G Witherspoon, Jonathan R Hall, Dereje Jima, Hannah M Atkins, Nathan T Wamsley, Michael B Major, Bernard E Weissman, Robert C Smart

Redox Biology · 2024

DOI: 10.1016/j.redox.2024.103261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Redox Biology, 2024. Verfasst von John G Witherspoon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, North Carolina State University, USA. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Skin Neoplasms, Keratinocytes, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Squamous cell carcinomas (SCCs), including lung, head & neck, bladder, and skin SCCs often display constitutive activation of the KEAP1-NRF2 pathway. Constitutive activation is achieved through multiple mechanisms, including activating mutations in NFE2L2 (NRF2). To determine the functional consequences of Nrf2 activation on skin SCC development, we assessed the effects of mutant Nrf2E79Q expression, one of the most common activating mutations in human SCCs, on tumor promotion and progression in the mouse skin multistage carcinogenesis model using a DMBA-initiation/TPA-promotion protocol where the Hras A->T mutation (Q61L) is the canonical driver mutation. Nrf2E79Q expression was temporally and conditionally activated in the epidermis at two stages of tumor development: 1) after DMBA initiation in the epidermis but before cutaneous tumor development and 2) in pre-existing DMBA-initiated/TPA-promoted squamous papillomas. Expression of Nrf2E79Q in the epidermis after DMBA initiation but before tumor occurrence inhibited the development/promotion of 70% of squamous papillomas. However, the remaining papillomas often displayed non-canonical Hras and Kras mutations and enhanced progression to SCCs compared to control mice expressing wildtype Nrf2. Nrf2E79Q expression in pre-existing tumors caused rapid regression of 60% of papillomas. The remaining papillomas displayed the expected canonical Hras A->T mutation (Q61L) and enhanced progression to SCCs. These results demonstrate that mutant Nrf2E79Q enhances the promotion and progression of a subset of skin tumors and alters the frequency and diversity of oncogenic Ras mutations when expressed early after initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2Skin NeoplasmsKeratinocytesMutationAnimalsMiceDisease ProgressionProto-Oncogene Proteins p21(ras)9,10-Dimethyl-1,2-benzanthraceneHumansCarcinoma, Squamous CellDisease Models, AnimalGene Expression Regulation, NeoplasticTetradecanoylphorbol Acetate

Stichwörter der Autor:innen

CancerConversionKEAP1Mouse skin multistage carcinogenesis modelNFE2L2Nrf2PapillomaProgressionPromotionProteomicsRNAseqRasSquamous cell carcinoma

Substanzen

NF-E2-Related Factor 2Nfe2l2 protein, mouseProto-Oncogene Proteins p21(ras)9,10-Dimethyl-1,2-benzanthraceneTetradecanoylphorbol Acetate

Autor:innen und Institutionen

  • Department of Biological Sciences, North Carolina State University, USA.
  • Department of Biological Sciences, North Carolina State University, USA; Toxicology Graduate Program, North Carolina State University, USA; Center for Human Health and the Environment, North Carolina State University, U…
  • Center for Human Health and the Environment, North Carolina State University, USA.
  • Center for Human Health and the Environment, North Carolina State University, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, USA.
  • Department of Cell Biology and Physiology, Washington University at St Louis, USA.
  • Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill School of Medicine, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicin…

Förderung

  • NCI NIH HHS

Zitieren

APA

Witherspoon, J. G., Hall, J. R., Jima, D., Atkins, H. M., Wamsley, N. T., Major, M. B., Weissman, B. E., & Smart, R. C. (2024). Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors. Redox Biology. https://doi.org/10.1016/j.redox.2024.103261

Vancouver

Witherspoon JG, Hall JR, Jima D, Atkins HM, Wamsley NT, Major MB, et al. Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors. Redox Biology. 2024. doi:10.1016/j.redox.2024.103261

BibTeX
@article{Witherspoon2024,
  author = {Witherspoon, John G and Hall, Jonathan R and Jima, Dereje and Atkins, Hannah M and Wamsley, Nathan T and Major, Michael B and Weissman, Bernard E and Smart, Robert C},
  title = {Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors},
  journal = {Redox Biology},
  year = {2024},
  doi = {10.1016/j.redox.2024.103261}
}
Kostenlos starten →